Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

oduct liability, supply, competition and other risks).

-more-

(Financial Table Attached)

ENTREMED, INC.

SUMMARY OF OPERATING RESULTS

Three Months Ended

September 30,

2008 2007

Total revenues $3,501,307 $3,520,259

Research and development 4,957,067 5,109,257

General and administrative 1,551,900 1,706,451

Acquired in-process research and development 0 0

Net Loss (3,397,877) (3,035,346)

Net Loss per share (basic and diluted)

attributable to common shareholders $(0.04) $(0.04)

Weighted average number of shares

outstanding (basic and diluted) 87,728,644 84,223,912

Nine Months Ended

September 30,

2008 2007

Total revenues $3,501,307 $3,520,259

Research and development 16,629,127 18,089,240

General and administrative 5,274,585 5,407,588

Acquired in-process research and development 2,000,000 0

Net Loss (21,314,476) (18,643,625)

Net Loss per share (basic)

attributable to common shareholders $(0.26) $(0.23)

Weighted average number of shares

outstanding (basic) 86,060,438 84,015,999

Ca
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... -- GenVec, Inc. (NASDAQ: GNVC ) today announced the ... board of directors effective on October 24, 2014.   Dr. Horovitz ... its chairman from June 2006 to November 2013.  During his ... and Audit Committees of the board.  "We ... service to GenVec, and its stockholders," said Wayne T. ...
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... Many biopharmaceuticals comprise small proteins that are quickly eliminated ... (TUM) combine such small proteins with a kind of ... of the proteins in the body. The TUM spin-off ... new technology with blockbuster potential. People who suffer ...
... The Center for Business Intelligence (CBI) announced today that ... Alzheimer,s Drug Development Summit to the Alzheimer,s Association. CBI will ... 2009, in recognition of World Alzheimer,s Day. , , ... raise awareness and encourage citizens to take action against the ...
... NEW YORK, Sept. 21 Emissary Capital Group, Inc. ... Bulletin Board: SNBP) with a Buy rating and target ... as Dong Ying Pharmaceutical Co. Ltd., is a fully ... manufacture and distribution of biopharmaceutical products. The company ...
Cached Biology Technology:Researchers prolong the plasma half-life of biopharmaceutical proteins 2Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association 2Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association 3Emissary Capital Group Initiates Coverage on Sinobiopharma 2
(Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst ... time half of the world,s population will have a ... Europe . Asia ... the market accounting for more than 60% of all ... Acuity,s report  -- "The Global National eID ...
(Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
Breaking Biology News(10 mins):Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Modeling tumor dormancy 2
... is your goal, you can't do better than to emulate ... and an unusual pitching stroke that allows the bug to ... is a marvel of engineering. , Z. Jane Wang, professor ... research on flying systems and fluid dynamics today (Feb. 19) ...
... at The Zucker Hillside Hospital campus of The ... of a gene that appears to influence intelligence. ... Center for Genetics and Genomics in Boston, the ... individuals with schizophrenia, a neuropsychiatric disorder characterized by ...
... scientists and doctors with the Physicians Committee for Responsible ... grow live cells in the laboratory. At issue is ... by puncturing the heart of a fetal calf without ... in a medium free of animal serum, enabling scientists ...
Cached Biology News:Scientist uses dragonflies to better understand flight 2Feinstein researchers identify intelligence gene 2
...
... is the first fully genetically encoded fluorescent ... intracellular hydrogen peroxide (H2O2), one of the ... the basis of yellow fluorescent protein inserted ... protein OxyR (OxyR-RD), HyPer demonstrates submicromolar affinity ...
Alexa Fluor 647 anti-mouse Qa-2...
... essential for hunting and analyzing the ... as EST sequencing projects, microarrays, functional ... is developed for normalization of cDNA ... for directional cloning. While most normalization ...
Biology Products: